【摘要】 [目的]评价改良的密集EC序贯紫杉醇每周给药方案用于高危乳腺癌患者术后密集化疗的临床疗效和安全性。[方法]62例高危复发乳腺癌患者,术后随机分成密集组31例,常规组31例。密集组接受双周EC方案4个疗程,序贯紫杉醇每周疗法10周化疗。常规组接受3周EC方案4个疗程,序贯紫杉醇3周方案4个疗程化疗。[结果]中位随访38个月后,密集组与常规组的3年无瘤生存率分别为87.1%和77.4%(P=0.174),3年总生存率分别为90.3%和87.1%,差异均无统计学意义(P=0.710)。两组治疗毒性均可耐受,其中在预防性GCSF支持下密集组的白细胞减少发生率为67.7%,而常规组为83.9%,差异无统计学意义(P=0.064)。[结论]以紫杉醇周疗法改良标准密集EC→P方案用于高危乳腺癌辅助化疗疗效较好,治疗毒性可耐受,值得临床进一步研究。更多还原

【Abstract】 [Purpose] To evaluate the efficacy and safety of modified dose-dense epirubicin/ cyclophosphamide(EC) follow by weekly paclitaxel regimen in the adjuvant chemotherapy for highrisk breast cancer. [Methods] A total of 62 postoperative patients with high-risk breast cancer were randomized into the dose-dense group(n=31) and the regular group(n=31). The dose-dense group received 2-week EC for 4 cycles follow by weekly paclitaxel for 10 weeks. The regular group received 3-week EC for 4 cycles follow by 3-week paclitaxel for 4 cycles. [Results] After a median follow-up of 38 months,the 3-year disease-free survival(DFS) rate in the dose-dense group and the regular group was 87.1% and 77.4%(P=0.174) respectively,the 3-year overall survival(OS) was 90.3% and 87.1%(P=0.710). There was no statistical significance between the two groups.The treatment toxicity in both groups was tolerable. With the support of granulocyte colony-stimulating factor,the rate of leukopenia in dose-dense group was lower than that in regular group( 67.7% vs 83.9%,P =0.064). [Conclusion] Modified dose-dense EC follow by weekly paclitaxel regimen in the adjuvant chemotherapy for high-risk breast cancer is effective and tolerable. It is worth further research.更多还原